Asep Medical Holdings Inc. Secures US Patent Approval for AI-Powered Sepsis Diagnostic Technology

In a significant stride towards revolutionizing sepsis diagnostics, Asep Medical Holdings Inc. (Asep Inc.) has attained US patent approval for its cutting-edge AI-based sepsis diagnostic technology, known as SepsetER^TM. This patented innovation, governed under US Patent Application No. 16/279788, fortifies the Company’s exclusive licensing to its subsidiary, Sepset Biosciences Inc. This pivotal achievement follows the successful acquisition of European and Australian patents in November 2022, collectively spanning an estimated population of 700 million.

The granted US patent, dated August 18, 2023, bolsters the credibility of Asep Inc.’s distinctive AI-driven approach to sepsis diagnosis. Developed under the guidance of Dr. Robert E. W. Hancock, a renowned microbiologist and Asep Inc.’s Founder, Chair & CEO, the SepsetER TM technology is poised to revolutionize early risk assessment for sepsis – a condition accounting for over 11 million global deaths annually and notably identified as a leading cause of mortality in severe COVID-19 cases.

The US patent is a critical milestone empowering Asep Inc.’s strategic pursuits, particularly advancing the SepsetER TM test through formal clinical 510(k) studies in the United States. These pivotal studies, a precursor to FDA approval, aim to leverage the technology’s validated signatures from over 700 sepsis and severe COVID-19 patients. The SepsetER TM test holds promise for expediting diagnostic timelines, providing results within 60-90 minutes compared to the current 8-36 hours, thereby facilitating prompt treatment initiation in emergency rooms and intensive care units globally.

CEO Dr. Robert E. W. Hancock emphasized, “Patents are the lifeblood of biotechnology companies like ours. This new patent in the US once again validates the novelty of our technology in major markets, which now represents over 700 million people.”

A Deep Dive into Asep Medical Holdings Inc.’s Innovations

Asep Medical Holdings Inc. stands committed to addressing the escalating global challenge of antibiotic resistance. The Company, a consolidation of three entities – Sepset Biosciences Inc., ABT Innovations Inc., and SafeCoat Medical Inc., is at the forefront of developing groundbreaking solutions for pressing medical needs.

Sepset Biosciences Inc.: Finalizing preparations for clinical studies and commercialization of an in vitro diagnostic test, Sepset Biosciences is pioneering the SepsetERtest. This blood-based gene expression assay stands as a rapid, accessible diagnostic tool, enabling risk assessment for severe sepsis within an hour of testing. The technology, validated through extensive trials, promises to revolutionize early decision-making for physicians, mitigating sepsis-related morbidity and mortality significantly.

ABT Innovations Inc.: With a diverse peptide technology portfolio encompassing therapeutic applications, ABT Innovations is in the pre-clinical development phase. Their technology exhibits promising potential across multiple fronts, addressing bacterial biofilm infections, anti-inflammatories, immune-modulators, and vaccine adjuvants.

SafeCoat Medical Inc.: Specializing in anti-fouling self-assembling polymers combined with antimicrobial peptides, SafeCoat Medical’s coatings demonstrate immense potential for various medical devices and implants. With successful demonstrations in animal models, their innovation heralds a promising future in preventing infections associated with medical devices.

Asep Medical Holdings Inc.’s success in securing a US patent for its AI-based SepsetER technology represents a significant leap forward in the realm of sepsis diagnostics. Their relentless pursuit of innovation and commitment to addressing critical medical needs underscore a promising future, offering hope for improved patient care and outcomes globally.